Source:http://linkedlifedata.com/resource/pubmed/id/10877053
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
2 Suppl 5
|
| pubmed:dateCreated |
2000-7-27
|
| pubmed:abstractText |
Within this phase II trial of the European Organization for Research and Treatment of Cancer, we have investigated the safety and efficacy of pentostatin (Nipent; SuperGen, San Ramon, CA) in refractory lymphoid malignancies. Pentostatin was administered at a dosage of 4 mg/m2 every week for the first 3 weeks, then every 14 days, followed by maintenance therapy of 4 mg/m2 monthly for a maximum of 6 months. We have previously reported the results in T- and B-cell prolymphocytic leukemia, B-cell chronic lymphocytic leukemia, and hairy cell leukemia This report focuses on the outcome in T-cell malignancies: T-cell chronic lymphocytic leukemia, Sézary syndrome, mycosis fungoides, and T-zone lymphoma. Of 92 patients with these diagnoses enrolled, 76 were evaluable for response and toxicity, ie, 25 of 28 with T-cell chronic lymphocytic leukemia, 21 of 26 with Sézary syndrome, 22 of 26 with mycosis fungoides, and eight of 12 with T-zone lymphoma. All patients had progressive and advanced disease. Sixteen patients (21%) died during the first 9 weeks of treatment: 12 of progressive disease, two of infectious complications thought to be unrelated to treatment, one of myocardial infarction, and one of renal failure related to administration of intravenous contrast. Major toxicity (grades 3 and 4) included infection in 10.5% of patients, nausea/vomiting in 5%, and hepatotoxicity in 3%. One patient (1.3%) achieved a complete remission and 15 (19.7%) a partial remission. Better results were achieved in patients with Sézary syndrome or mycosis fungoides (complete remission + partial remission = 33.4% and 22.7%, respectively) than in patients with T-cell chronic lymphocytic leukemia (8%) or T-zone lymphoma (25%). We conclude that pentostatin is active in low-grade T-cell malignancies. Toxicities are mild to moderate at the dose schedule administered. Severe hematologic toxicity has not been observed. The efficacy at the present dose level is moderate. A higher dose might be necessary for some T-cell malignancies.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Apr
|
| pubmed:issn |
0093-7754
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
27
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
52-7
|
| pubmed:dateRevised |
2007-11-15
|
| pubmed:meshHeading |
pubmed-meshheading:10877053-Adult,
pubmed-meshheading:10877053-Aged,
pubmed-meshheading:10877053-Antibiotics, Antineoplastic,
pubmed-meshheading:10877053-Cause of Death,
pubmed-meshheading:10877053-Disease Progression,
pubmed-meshheading:10877053-Dose-Response Relationship, Drug,
pubmed-meshheading:10877053-Drug Administration Schedule,
pubmed-meshheading:10877053-Female,
pubmed-meshheading:10877053-Humans,
pubmed-meshheading:10877053-Immunosuppressive Agents,
pubmed-meshheading:10877053-Leukemia, Hairy Cell,
pubmed-meshheading:10877053-Leukemia, Lymphocytic, Chronic, B-Cell,
pubmed-meshheading:10877053-Leukemia, Prolymphocytic,
pubmed-meshheading:10877053-Leukemia, T-Cell,
pubmed-meshheading:10877053-Lymphoma, T-Cell,
pubmed-meshheading:10877053-Male,
pubmed-meshheading:10877053-Middle Aged,
pubmed-meshheading:10877053-Mycosis Fungoides,
pubmed-meshheading:10877053-Pentostatin,
pubmed-meshheading:10877053-Remission Induction,
pubmed-meshheading:10877053-Sezary Syndrome,
pubmed-meshheading:10877053-Skin Neoplasms,
pubmed-meshheading:10877053-Treatment Outcome
|
| pubmed:year |
2000
|
| pubmed:articleTitle |
Pentostatin (Nipent) in T-cell malignancies. Leukemia Cooperative Group and the European Organization for Research and Treatment of Cancer.
|
| pubmed:affiliation |
Department of Medicine, University of Heidelberg, Germany.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Multicenter Study,
Clinical Trial, Phase II
|